C. David Nicholson
CIK: 0001636168
Transaction Breakdown
High conviction signal
Position reduction
Derivative conversions
Compensation grants
Gifts, tax withholding, conversions, dispositions to the issuer and other codes
Discretionary Trading P&L
Holdings
Transaction History (13 total)
- Sep 2, 2026ATNM
Actinium Pharmaceuticals, Inc.
Award(A)Direct62.8K shares- - Dec 9, 2025ADVM
Adverum Biotechnologies, Inc.
Disposition(D)DirectStock Option (Right to Buy)
8K shares- - Dec 9, 2025ADVM
Adverum Biotechnologies, Inc.
Disposition(D)DirectStock Option (Right to Buy)
10.5K shares- - Dec 9, 2025ADVM
Adverum Biotechnologies, Inc.
Disposition(D)DirectStock Option (Right to Buy)
10.5K shares- - Jun 17, 2025ADVM
Adverum Biotechnologies, Inc.
Award(A)DirectStock Option (Right to Buy)
10.5K shares- - Mar 31, 2025ATNM
Actinium Pharmaceuticals, Inc.
Disposition(D)DirectStock Option (Right to Buy)
2.5K shares- - Mar 31, 2025ATNM
Actinium Pharmaceuticals, Inc.
Disposition(D)DirectStock Option (Right to Buy)
2.5K shares- - Mar 31, 2025ATNM
Actinium Pharmaceuticals, Inc.
Disposition(D)DirectStock Option (Right to Buy)
2.5K shares- - Mar 31, 2025ATNM
Actinium Pharmaceuticals, Inc.
Disposition(D)DirectStock Option (Right to Buy)
8.3K shares- - Mar 31, 2025ATNM
Actinium Pharmaceuticals, Inc.
Disposition(D)DirectStock Option (Right to Buy)
8.3K shares- - Mar 31, 2025ATNM
Actinium Pharmaceuticals, Inc.
Disposition(D)DirectStock Option (Right to Buy)
18.4K shares- - Mar 31, 2025ATNM
Actinium Pharmaceuticals, Inc.
Disposition(D)DirectStock Option (Right to Buy)
72.2K shares- - Mar 31, 2025ATNM
Actinium Pharmaceuticals, Inc.
Disposition(D)DirectStock Option (Right to Buy)
70.3K shares-
| Type | Shares | Price | Ownership | |||
|---|---|---|---|---|---|---|
| Sep 2, 2026 |  ATNM Actinium Pharmaceuticals, Inc. | Award(A) | 62,800 | - | $0 | Direct |
| Dec 9, 2025 |  ADVM Adverum Biotechnologies, Inc. | Disposition(D) Stock Option (Right to Buy) | 8,000 | - | - | Direct |
| Dec 9, 2025 | ADVM Adverum Biotechnologies, Inc. | Disposition(D) Stock Option (Right to Buy) | 10,520 | - | - | Direct |
| Dec 9, 2025 | ADVM Adverum Biotechnologies, Inc. | Disposition(D) Stock Option (Right to Buy) | 10,450 | - | - | Direct |
| Jun 17, 2025 | ADVM Adverum Biotechnologies, Inc. | Award(A) Stock Option (Right to Buy) | 10,450 | - | - | Direct |
| Mar 31, 2025 | ATNM Actinium Pharmaceuticals, Inc. | Disposition(D) Stock Option (Right to Buy) | 2,500 | - | - | Direct |
| Mar 31, 2025 | ATNM Actinium Pharmaceuticals, Inc. | Disposition(D) Stock Option (Right to Buy) | 2,500 | - | - | Direct |
| Mar 31, 2025 | ATNM Actinium Pharmaceuticals, Inc. | Disposition(D) Stock Option (Right to Buy) | 2,500 | - | - | Direct |
| Mar 31, 2025 | ATNM Actinium Pharmaceuticals, Inc. | Disposition(D) Stock Option (Right to Buy) | 8,333 | - | - | Direct |
| Mar 31, 2025 | ATNM Actinium Pharmaceuticals, Inc. | Disposition(D) Stock Option (Right to Buy) | 8,333 | - | - | Direct |
| Mar 31, 2025 | ATNM Actinium Pharmaceuticals, Inc. | Disposition(D) Stock Option (Right to Buy) | 18,351 | - | - | Direct |
| Mar 31, 2025 | ATNM Actinium Pharmaceuticals, Inc. | Disposition(D) Stock Option (Right to Buy) | 72,156 | - | - | Direct |
| Mar 31, 2025 | ATNM Actinium Pharmaceuticals, Inc. | Disposition(D) Stock Option (Right to Buy) | 70,311 | - | - | Direct |
1-13 of 13 transactions
About Nicholson, C. David
Nicholson, C. David (SEC CIK 0001636168) files insider reports with the SEC as Director of Actinium Pharmaceuticals, Inc. (ATNM) and Director of Adverum Biotechnologies, Inc. (ADVM).
Signal8 holds 4 ownership filings by Nicholson, C. David, all Form 4s, filed between Apr 2, 2025 and Sep 4, 2026. Those filings report 13 transactions, from Mar 31, 2025 to Sep 2, 2026. Signal8's Form 4 history starts in Sep 2024.
The business address on Nicholson, C. David's filings is in NEW YORK, NY.
Recent filings by Nicholson, C. David
- Sep 2, 2026: Grant or award of ATNM shares (Form 4, code A).
- Dec 9, 2025: Disposition to issuer transactions of ADVM derivative securities (3 lines, Form 4, code D).
- Jun 17, 2025: Grant or award of ADVM derivative securities (Form 4, code A).
- Mar 31, 2025: Disposition to issuer transactions of ATNM derivative securities (8 lines, Form 4, code D).
Other insiders filing for Actinium Pharmaceuticals, Inc. (ATNM)
- David Matthew T, Chief Financial Officer
- Kamal Adeela, Chief Scientific Officer
- Heeger Steffen Wilhem, Chief Medical Officer
- Shetty Ajit, Director
- Almenoff June Sherie, Director
- SETH SANDESH, Chief Executive Officer